- Eurobiomed, the leading cluster for innovation and industrialisation among healthcare companies in Southern France, supported 22 R&D projects in 2025, resulting in €142 million in public funding secured for its member companies in the Sud and Occitanie regions.
- In 2025, HealthTech companies in the Sud and Occitanie regions secured €309 million in private funding, including €160 million raised by Eurobiomed member companies, confirming the region’s momentum and the cluster’s structuring role in access to financing.
- Overall, the cluster’s action helped mobilise €302 million in public and private funding for its member companies, confirming the region’s dynamism and Eurobiomed’s structuring role in access to financing.
- Eurobiomed posted a record of more than 300 support and business connection missions involving healthcare companies, laboratories, university hospitals, institutional stakeholders and investors.
- Three priority strategic healthcare sectors have been identified for 2026: immunotherapy and regenerative medicine, digital health, and dermatology & skin science.
Eurobiomed, the leading cluster for innovation and industrialisation in the HealthTech sector in Southern France, has published its 2025 results and confirmed its role as a strategic accelerator supporting sector development, financing and the industrialisation of HealthTech innovation in the Sud and Occitanie regions, covering the metropolitan areas of Toulouse, Montpellier, Nice, Sophia Antipolis and Marseille.
More than 22 R&D projects supported by Eurobiomed in 2025 in a context of strong investor selectivity
In 2025, Eurobiomed confirmed its role as a structuring cluster in an environment that has become particularly demanding. HealthTech companies must now navigate a new funding landscape and increased complexity in terms of clinical, regulatory and industrial pathways. Although France benefits from world-class healthcare research, turning innovation into industrial solutions that are genuinely accessible to patients remains a major challenge. In this context, Eurobiomed is asserting itself as a key player in structuring the healthcare sector in Southern France and supports companies in scaling their innovations into fundable, industrialisable and marketable projects.
In 2025, Eurobiomed’s strategic support translated into more than 300 support and high-quality connection missions between companies, laboratories, university hospitals, institutional stakeholders and investors.
Overall, Eurobiomed member companies in the Sud and Occitanie regions secured €302 million in public and private funding in 2025.
This amount consists of €142 million in public funding obtained for 22 R&D projects supported by the cluster, including €100 million through France 2030, and €160 million in private funding for member companies supported by Eurobiomed during the year.
At regional level, all healthcare companies in the Sud and Occitanie regions secured €309 million in private funding in 2025. In this respect, Eurobiomed member companies alone accounted for more than half of this private funding, with €160 million raised in the region.
Of the €309 million in private funding raised by all companies in the Sud and Occitanie regions in 2025, €192.1 million (62%) concerned biotechnology, €86 million (28%) medtech, €20 million (6%) diagnostics and €11 million (4%) digital health.
This momentum is reflected in several emblematic industrial and financial successes. MedinCell reached a decisive milestone with the commercial launch in the United States of its long-acting injectable treatment. ImCheck Therapeutics was acquired by French biopharmaceutical group Ipsen, confirming the attractiveness of innovations developed in the region. Finally, Adcytherix completed a €105 million Series A funding round in 2025, the largest fundraising round by a French biotech company that year.
A growing community with more than 100 new Eurobiomed members in 2025 and a strengthened expert board
With 432 members, including 106 new members in 2025, Eurobiomed has reached its highest-ever membership level. This strong re-engagement rate reflects the relevance of a support model based on comprehensive engineering, combining strategic guidance, targeted connections with clinical and industrial stakeholders, and support towards access to financing.
Focus on the Eurobiomed expert board
Eurobiomed relies on a board of nearly 60 high-level experts from industry, academia and research, mobilised to support HealthTech companies at every stage of their development. In 2025, in addition to the scientific experts dedicated to supporting R&D projects, Eurobiomed structured a pool of successful entrepreneur and industrial experts, including Pierre d’Epenoux, CEO of ImCheck Therapeutics, Fabienne Hermitte, co-founder of Ipsogen, and Christine Guillem, CEO of Angany.
Tailor-made support schemes created by Eurobiomed to secure companies’ funding pathways and scaling-up trajectories
In order to provide operational and strategic support to companies in a context of strong selectivity in financing and industrial and scientific partnerships, Eurobiomed has structured a support offer adapted to the different stages of company maturity through dedicated premium programmes.
Focus on the Invest In Biomed programme, dedicated to financing strategies
The Invest In Biomed programme, dedicated to supporting HealthTech companies in their fundraising strategy, illustrates Eurobiomed’s ability to connect the ecosystem effectively with investors. In 2025, it brought together 9 innovative companies and 37 specialised investors, resulting in more than 130 B2B meetings.
Orchestrated with 15 Eurobiomed experts, the support was built around a pathway focused on companies’ strategic diagnosis, their understanding of investor expectations and the structuring of their value proposition. The programme’s highlight, organised in Marseille, enabled companies to present their projects to specialised investors and receive direct operational feedback. In this context, a company such as Eka Surgery, which is developing an artificial intelligence platform designed to assist surgeons, was able to enter into active discussions with financial partners, while Circle Safe, which had taken part in a previous Invest In Biomed cohort, raised €8 million in 2025 for its innovative solution aimed at securing atrial fibrillation ablation procedures.
Three high-potential strategic healthcare sectors identified for 2025–2026
Eurobiomed promotes a sector-based approach to supporting healthcare companies and identifies themes with strong growth potential, in line with the maturity of the HealthTech base and the projects present in its territories. Eurobiomed has therefore focused its action on three priority sectors: immunotherapies and regenerative medicine, digital health, and dermatology and skin science.
Immunotherapies and regenerative medicine, driven in particular by the momentum of the Marseille Immunology Biocluster, are at the heart of the innovative therapies market. These applications represent one of the most dynamic segments of the global pharmaceutical industry, with a market valued at several hundred billion dollars.
Digital health, for its part, is emerging as a cross-cutting driver of innovation and transformation in healthcare systems. The global digital health market is estimated at more than $400 billion in 2025, driven by the growth of artificial intelligence and connected medical devices.
Focus on the dermatology and skin science sector: Skin Excellence by Eurobiomed, an unprecedented international project
Eurobiomed has decided to prioritise the structuring of the dermatology and skin science sector, a segment at the crossroads of medical dermatology, cosmetics and biotechnology. The global skincare market is estimated at around $178 billion in 2025, while the more specialised dermocosmetics segment, at the intersection of cosmetics and health, represents nearly $48 billion and continues to grow strongly.
With more than 80 stakeholders, including startups, academic laboratories, industrial companies and hospitals, the Skin sector in Occitanie and the Sud region already accounts for nearly 4,000 jobs and represents strong growth potential. Based on this mapping, Eurobiomed has launched operational structuring work for the sector, built around four areas:
- The mapping of stakeholders to guide Skin Excellence’s priority themes and target relevant business connections between players.
- Visibility and networking, with the launch of the official Skin Excellence website and partnerships with major organisations such as La Roche-Posay, Beiersdorf and others.
- The organisation of major events. For example, the first Skin Summit brought together nearly 200 participants from more than 10 countries, positioning the Skin sector in Southern France at an unprecedented level in terms of international visibility. Building on this success, a second edition will be organised in 2027.
- The development of structuring projects to support innovation and industrialisation. Eurobiomed notably worked on the project engineering of the Skin Experimentation Third Place, a scheme designed to facilitate the testing and validation phases of skin health innovations, financed to the tune of €1 million through France 2030.
2026 outlook: value chains, industrialisation and the expansion of premium programmes
In 2026, Eurobiomed intends to continue and scale up the action launched in 2025 in order to accelerate the growth of HealthTech companies in the Sud and Occitanie regions. The cluster intends to continue structuring its strategic sectors, with the objective of accelerating their internationalisation.
Eurobiomed also plans to strengthen and expand its expert board in order to support entrepreneurs even more precisely in defining and executing their development strategies, beyond financing issues alone. This momentum will be accompanied by the launch of a support programme dedicated to CROs (private research service companies for the pharmaceutical industry). Lastly, Eurobiomed plans to roll out a support programme dedicated to bringing digital health tools to market.
Emilie Royère, Chief Executive Officer of Eurobiomed, concludes:
“HealthTech companies are no longer looking only for support in innovation or access to financing. They need comprehensive strategic guidance capable of covering their entire trajectory, from project structuring through to industrialisation and market access.
In 2025, Eurobiomed strengthened this positioning by supporting companies very concretely at these key stages, whether in the structuring of complex projects, financing, regulation, business connections or preparation for industrialisation. The results achieved, both in terms of network momentum and the scaling-up of supported companies, confirm the relevance of this approach.
In 2026, we will continue our commitment to structuring strategic sectors capable of bringing French HealthTech champions to the international stage.”
Source: Eurobiomed press release
